Analysis of the status of provision of pharmaceutical care to patients with multiple sclerosis in Ukraine

Authors

DOI:

https://doi.org/10.15587/2519-4852.2025.329991

Keywords:

multiple sclerosis, pharmaceutical care, drugs, pharmacist

Abstract

Considering modern approaches to the treatment of chronic non-communicable diseases, as well as the experience of active involvement of pharmacists in multidisciplinary teams of healthcare professionals, it is relevant to determine the professional role of a pharmacist in teams providing medical and social care to patients with multiple sclerosis (MS).

The aim: to analyze the state of pharmaceutical care (PC) provision to Ukrainian patients with multiple sclerosis (MS).

Materials and methods. The study is based on scientific works of domestic and foreign researchers on this problem, regulatory documents on the provision of medical care to patients with MS and the results of a sociological survey of patients diagnosed with MS. The study used methods of scientific information search, narrative approach, generalization, survey, statistical analysis, and others.

Results. The pharmaceutical component of the medical care process was determined and a list of drugs used in the complex therapy of MS was determined: H02AB - glucocorticoids, L01BB - structural purine analogues, L01FA - CD 20 inhibitors, L03AB - interferons, L04AA - selective immunosuppressants, L04AG - monoclonal antibodies, L04AX - other immunosuppressants.

The analysis of the availability of DMT drugs showed that only 75 % of the recommended drugs are physically available in Ukraine, with drugs with lower efficacy prevailing. The low availability of highly effective drugs (drugs) of the 3rd category for Ukrainian patients with MS is due to the lack of state funding for their purchase, which makes treatment with such drugs financially burdensome for patients.

The survey found that 64.5 % of patients would like to receive additional support from pharmacists. Possible elements of pharmaceutical care that are important for patients with MS were identified, such as counselling, coordination with public organizations, explanation of new treatment options, and symptom monitoring.

When assessing patients' adherence to PC, factors such as age, gender, location, displaced status, work restrictions, or time since diagnosis did not significantly influence patients' positive attitudes. Furthermore, these factors did not influence patients' preferences for preferred pharmacist interaction format (face-to-face, mixed, or telepharmacy).

Conclusions: There is a need to expand the availability and update the registration of drugs for the treatment of MS. Patients with MS have a positive attitude towards pharmaceutical care, but need more awareness of its possibilities. Social status affects the perception of the need for pharmaceutical care and the choice of the format of its provision

Author Biographies

Natalia Tkachenko, Zaporizhzhia State Medical and Pharmaceutical University

Doctor of Pharmaceutical Sciences, Professor, Head of  Department

Department of Pharmacy Management and Economics

Svitlana Ryzhkova, Zaporizhzhia State Medical and Pharmaceutical University

PhD Student

Department of Pharmacy Management and Economics

Anzhela Olkhovska, National Technical University «Kharkiv Polytechnic Institute»

Doctor Sciences of Pharmacy, Professor

Department of Organizations and Management Healthcare and Social Medicine

References

  1. Atlas MS. Multiple Sclerosis National Federation. Available at: https://www.atlasofms.org/map/global/epidemiology/number-of-people-newly-diagnosed-with-ms
  2. Liu, R., Du, S., Zhao, L., Jain, S., Sahay, K., Rizvanov, A. et al. (2022). Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.996469
  3. Moghaddam, V. K., Dickerson, A. S., Bazrafshan, E., Seyedhasani, S. N., Najafi, F., Hadei, M. et al. (2021). Socioeconomic determinants of global distribution of multiple sclerosis: an ecological investigation based on Global Burden of Disease data. BMC Neurology, 21 (1). https://doi.org/10.1186/s12883-021-02170-3
  4. von Drathen, S., Gold, S. M., Peper, J., Rahn, A. C., Ramien, C., Magyari, M. et al. (2024). Stress and Multiple Sclerosis – Systematic review and meta-analysis of the association with disease onset, relapse risk and disability progression. Brain, Behavior, and Immunity, 120, 620–629. https://doi.org/10.1016/j.bbi.2024.06.004;
  5. Jiang, J., Abduljabbar, S., Zhang, C., Osier, N. (2022). The relationship between stress and disease onset and relapse in multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders, 67, 104142. https://doi.org/10.1016/j.msard.2022.104142
  6. Bowen, J., Mehta, R., Pelletier, C., Tian, M., Noxon, V., Johnson, B. H., Bonafede, M. (2020). Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy. Advances in Therapy, 37 (7), 3163–3177. https://doi.org/10.1007/s12325-020-01367-1
  7. Shah, P. (2015). Symptomatic management in multiple sclerosis. Annals of Indian Academy of Neurology, 18 (5), 35–42. https://doi.org/10.4103/0972-2327.164827
  8. Talanki Manjunatha, R., Habib, S., Sangaraju, S. L., Yepez, D., Grandes, X. A. (2022). Multiple Sclerosis: Therapeutic Strategies on the Horizon. Cureus, 14 (5), e24895. https://doi.org/10.7759/cureus.24895
  9. Beretich, B., Beretich, T. (2009). Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis. Multiple Sclerosis Journal, 15 (8), 891–898. https://doi.org/10.1177/1352458509105579
  10. Mahat, K., Thapa, B. (2019). Multi-sectoral Approach to Non-Communicable Diseases Control: Easier Said than Done. Journal of Nepal Medical Association, 57 (220), 467–470. https://doi.org/10.31729/jnma.4729
  11. Rahayu, S. A., Widianto, S., Defi, I. R., Abdulah, R. (2021). Role of Pharmacists in the Interprofessional Care Team for Patients with Chronic Diseases. Journal of Multidisciplinary Healthcare, 14, 1701–1710. https://doi.org/10.2147/jmdh.s309938
  12. Angibaud, M., Jourdain, M., Girard, S., Rouxel, L., Mouhib, A., Nogueira, A. et al. (2024). Involving community pharmacists in interprofessional collaboration in primary care: a systematic review. BMC Primary Care, 25 (1). https://doi.org/10.1186/s12875-024-02326-3
  13. Kotvitska, A., Volkova, A., Nozdrina, A., Surikova, I. (2024). Determination of the socially oriented role of pharmacists in the prevention, diagnosis and treatment of patients with viral hepatitis. ScienceRise: Pharmaceutical Science, 5 (51), 104–112. https://doi.org/10.15587/2519-4852.2024.314295
  14. Resolution CM/Res (2020)3 on the implementation of pharmaceutical care for the benefit of patients and Health services: Resolution no. CM/Res (2020)3. Council of Europe. Available at: https://rm.coe.int/09000016809cdf26
  15. Sukhera, J. (2022). Narrative Reviews: Flexible, Rigorous, and Practical. Journal of Graduate Medical Education, 14 (4), 414–417. https://doi.org/10.4300/jgme-d-22-00480.1
  16. International Ethical Guidelines for Health-related Research Involving Humans (2016). Geneva: Council for International Organizations of Medical Sciences (CIOMS). Available at: https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf
  17. Albert, B., Tullis, T., Tedesco, D. (2010). Planning the Study. Beyond the Usability Lab, 17–47. https://doi.org/10.1016/b978-0-12-374892-8.00002-8
  18. Jager, J., Putnick, D. L., Bornstein, M. H. (2017). II. More than just convenient: the scientific merits of homogeneous convenience samples. Monographs of the Society for Research in Child Development, 82 (2), 13–30. https://doi.org/10.1111/mono.12296
  19. Rossi, R. J. (2018). Mathematical Statistics: An Introduction to Likelihood Based Inference. New York: John Wiley & Sons. 227. https://doi.org/10.1002/9781118771075
  20. Osnovy zakonodavstva Ukrainy pro okhoronu zdorovia (1992). Zakon Ukrainy No. 2801-XII. 19.11.1992. Available at: https://zakon.rada.gov.ua/laws/show/2801-12#Text
  21. Pro derzhavni finansovi harantii medychnoho obsluhovuvannia naselennia (2017). Zakon Ukrainy No. 2168-VIII. 19.10.2017. Available at: https://zakon.rada.gov.ua/laws/show/2168-19#Text
  22. Pro likarski zasoby (1996). Zakon Ukrainy No. 123/96-VR. 04.04.1996. Available at: https://zakon.rada.gov.ua/laws/show/123/96-%D0%B2%D1%80#Text
  23. Deiaki pytannia zakupivli likarskykh zasobiv, medychnykh vyrobiv ta dopomizhnykh zasobiv do nykh (2022). Postanova KM Ukrainy No. 216. 07.03.2022. Available at: https://zakon.rada.gov.ua/laws/show/216-2022-%D0%BF?find=1&text=%D1%80%D0%BE%D0%B7%D1%81%D1%96%D1%8F%D0%BD%D0%B8%D0%B9+%D1%81%D0%BA%D0%BB%D0%B5%D1%80%D0%BE%D0%B7#w1_2
  24. Novyi klinichnyi protokol medychnoi dopomohy rozsiianyi skleroz u doroslykh (2024). Nakaz MOZ Ukrainy No. 1142. 01.07.2024. Available at: https://www.dec.gov.ua/wp-content/uploads/2024/07/nkpmd-rs-z-nomerom-pdf.pdf
  25. Likuvannia boliu ta spastychnosti v patsiientiv iz rozsiianym sklerozom (2024). NEIRONEWS© Zbirnyk klinichnykh rekomendatsii, 84–91. Available at: https://neuronews.com.ua/uploads/sborniki/2024/articles/articles/nn-zkr-24__84-91.pdf
  26. Gozzo, L., Romano, G. L., Brancati, S., Longo, L., Vitale, D. C., Drago, F. (2023). The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1169400
  27. Pro vnesennia zmin do pereliku likarskykh zasobiv ta medychnykh vyrobiv, yaki zakupovuiutsia na pidstavi uhod shchodo zakupivli iz spetsializovanymy orhanizatsiiamy, yaki zdiisniuiut zakupivli za napriamamy vykorystannia biudzhetnykh koshtiv u 2018 rotsi za prohramoiu “Zabezpechennia medychnykh zakhodiv okremykh derzhavnykh prohram ta kompleksnykh zakhodiv prohramnoho kharakteru” (2018). Postanova KMU No. 520. 20.06.2018. Available at: https://zakon.rada.gov.ua/laws/show/520-2018-%D0%BF#Text
  28. Vysnovok upovnovazhenoho orhanu z derzhavnoi otsinky medychnykh tekhnolohii: kladrybin (2023). Derzhavne pidpryiemstvo «derzhavnyi ekspertnyi tsentr ministerstva okhorony zdorovia Ukrainy», 43. Available at: https://www.dec.gov.ua/wp-content/uploads/2022/02/vysnovok-z-derzhavnoyi-omt-kladrybin-mavenklad-vid-14.08.2023.pdf
  29. Vysnovok upovnovazhenoho orhanu z derzhavnoi otsinky tekhnolohii: okrelizuma (2023). Derzhavne pidpryiemstvo «derzhavnyi ekspertnyi tsentr ministerstva okhorony zdorovia Ukrainy», 32. Available at: https://www.dec.gov.ua/wp-content/uploads/2022/02/vysnovok-z-derzhavnoyi-omt-okrelizumab-vid-05.07.2023.pdf
  30. Vysnovok upovnovazhenoho orhanu z derzhavnoi otsinky tekhnolohii: alemtuzumab (2023). Derzhavne pidpryiemstvo «derzhavnyi ekspertnyi tsentr ministerstva okhorony zdorovia Ukrainy», 21. Available at: https://www.dec.gov.ua/wp-content/uploads/2022/02/vysnovok-upovnovazhenogo-organu-z-derzhavnoyi-omt-lz-alemtuzumab-sajt.pdf
  31. Gasperini, C., Battaglia, M. A., Balzani, F., Chiarini, E., Pani, M., Pasqualetti, P. et al. (2024). Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionals. Journal of Neurology, 272 (1). https://doi.org/10.1007/s00415-024-12725-2
  32. Bauer, B., Brockmeier, B., Devonshire, V., Charbonne, A., Wach, D., Hendin, B. (2020). An International Discrete Choice Experiment Assessing patients’ Preferences for disease-modifying Therapy Attributes in Multiple Sclerosis. Neurodegenerative Disease Management, 10 (6), 369–382. https://doi.org/10.2217/nmt-2020-0034
  33. Li, P., Ladage, V. P., Berger, J., Chahin, S., Jhaveri, M., Geremakis, C., Doshi, J. A. (2020). Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis. Value in Health, 23 (3), 328–334. https://doi.org/10.1016/j.jval.2019.10.011
  34. Martínez-López, I., Maurino, J., Sanmartín-Fenollera, P., Ontañon-Nasarre, A., Santiago-Pérez, A., Moya-Carmona, I. et al. (2020). Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis. Pharmacy, 8 (2), 61. https://doi.org/10.3390/pharmacy8020061
  35. Flemmen, H. Ø., Simonsen, C. S., Broch, L., Brunborg, C., Berg-Hansen, P., Moen, S. M. et al. (2022). The influence of socioeconomic factors on access to disease modifying treatment in a Norwegian multiple sclerosis cohort. Multiple Sclerosis and Related Disorders, 61, 103759. https://doi.org/10.1016/j.msard.2022.103759
  36. Hadjigeorgiou, G., Dardiotis, E., Tsivgoulis, G., Doskas, T., Petrou, D., Makris, N. et al. (2014). Observational Study Assessing Demographic, Economic and Clinical Factors Associated with Access and Utilization of Health Care Services of Patients with Multiple Sclerosis under Treatment with Interferon Beta-1b (EXTAVIA). PLoS ONE, 9 (11), e113933. https://doi.org/10.1371/journal.pone.0113933
  37. Ruiz-Ramos, J., Hernández, M. H., Juanes-Borrego, A. M., Milà, R., Mangues-Bafalluy, M. A., Mestres, C. (2021). The Impact of Pharmaceutical Care in Multidisciplinary Teams on Health Outcomes: Systematic Review and Meta-Analysis. Journal of the American Medical Directors Association, 22 (12), 2518–2526. https://doi.org/10.1016/j.jamda.2021.05.038
  38. Kremin, Y., Lesyk, L., Lesyk, R., Levytska, O., Hromovyk, B. (2023). Detailing the Ten Main Professional Roles of a Pharmacist to Provide the Scope of Professional Functions. Scientia Pharmaceutica, 91 (1), 5. https://doi.org/10.3390/scipharm91010005
  39. Johnson, D. (2023). How to work effectively as part of a multidisciplinary team. Pharmaceutical Journal, 311 (7978). https://doi.org/10.1211/pj.2023.1.199023
Analysis of the status of provision of pharmaceutical care to patients with multiple sclerosis in Ukraine

Downloads

Published

2025-06-30

How to Cite

Tkachenko, N., Ryzhkova, S., & Olkhovska, A. (2025). Analysis of the status of provision of pharmaceutical care to patients with multiple sclerosis in Ukraine. ScienceRise: Pharmaceutical Science, (3 (55), 4–16. https://doi.org/10.15587/2519-4852.2025.329991

Issue

No. 3 (55) (2025)

Section

Pharmaceutical Science

License

Copyright (c) 2025 Natalia Tkachenko, Svitlana Ryzhkova, Аnzhela Olkhovska

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.